BioAge Labs Inc. Financials
This page shows BioAge Labs Inc. (BIOA) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 3 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Financial Health Signals
Based on FY2025 annual data. Scores normalized against common benchmarks. How we calculate these scores
BioAge Labs Inc. has an operating margin of -1031.5%, meaning the company retains $-1031 of operating profit per $100 of revenue. This below-average margin results in a low score of 0/100, suggesting thin profitability after operating expenses.
BioAge Labs Inc. carries a low D/E ratio of 0.01, meaning only $0.01 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 100/100, indicating a strong balance sheet with room for future borrowing.
With a current ratio of 14.24, BioAge Labs Inc. holds $14.24 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 100/100.
While BioAge Labs Inc. generated -$81.6M in operating cash flow, capex of $719K consumed most of it, leaving -$82.3M in free cash flow. This results in a low score of 0/100, reflecting heavy capital investment rather than weak cash generation.
BioAge Labs Inc. generates a -29.6% ROE, indicating limited profit relative to shareholders' investment. This results in a returns score of 0/100. This is down from -22.0% the prior year.
BioAge Labs Inc. passes 1 of 9 financial strength tests. No profitability signals pass, 1 of 3 leverage/liquidity signals pass.
For every $1 of reported earnings, BioAge Labs Inc. generates $1.01 in operating cash flow (-$81.6M OCF vs -$80.6M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
BioAge Labs Inc. earns $-132.5 in operating income for every $1 of interest expense (-$92.8M vs $700K). This narrow margin raises concern about the company's ability to service its debt if operating income declines.
Key Financial Metrics
Earnings & Revenue
BioAge Labs Inc. generated $9.0M in revenue in fiscal year 2025.
BioAge Labs Inc.'s EBITDA was -$92.6M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 18.7% from the prior year.
BioAge Labs Inc. reported -$80.6M in net income in fiscal year 2025. This represents a decrease of 13.4% from the prior year.
BioAge Labs Inc. earned $-2.24 per diluted share (EPS) in fiscal year 2025. This represents an increase of 66.2% from the prior year.
Cash & Balance Sheet
BioAge Labs Inc. generated -$82.3M in free cash flow in fiscal year 2025, representing cash available after capex. This represents a decrease of 58.7% from the prior year.
BioAge Labs Inc. held $188.9M in cash against $2.5M in long-term debt as of fiscal year 2025.
BioAge Labs Inc. had 44M shares outstanding in fiscal year 2025. This represents an increase of 23.8% from the prior year.
Margins & Returns
BioAge Labs Inc.'s operating margin was -1031.5% in fiscal year 2025, reflecting core business profitability.
BioAge Labs Inc.'s net profit margin was -896.1% in fiscal year 2025, showing the share of revenue converted to profit.
BioAge Labs Inc.'s ROE was -29.6% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is down 7.6 percentage points from the prior year.
Capital Allocation
BioAge Labs Inc. invested $74.0M in research and development in fiscal year 2025. This represents an increase of 25.3% from the prior year.
BioAge Labs Inc. invested $719K in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents an increase of 96.4% from the prior year.
BIOA Income Statement
| Metric | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $2.1M-14.8% | $2.4M+66.2% | $1.5M | N/A | $0 | $0 | N/A | N/A |
| Cost of Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D Expenses | $18.5M-6.7% | $19.8M+78.6% | $11.1M | N/A | $20.0M+91.2% | $10.5M+12.3% | $9.3M | N/A |
| SG&A Expenses | $6.7M-9.0% | $7.3M+8.1% | $6.8M | N/A | $4.7M-1.4% | $4.8M+37.4% | $3.5M | N/A |
| Operating Income | -$23.1M+6.6% | -$24.8M-50.6% | -$16.4M | N/A | -$24.8M-62.1% | -$15.3M-19.2% | -$12.8M | N/A |
| Interest Expense | $149K-25.9% | $201K-21.2% | $255K | N/A | $388K-12.4% | $443K-63.6% | $1.2M | N/A |
| Income Tax | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Income | -$20.2M+6.5% | -$21.6M-66.8% | -$12.9M | N/A | -$23.4M-72.4% | -$13.6M-4.5% | -$13.0M | N/A |
| EPS (Diluted) | $-0.56+6.7% | $-0.60-66.7% | $-0.36 | N/A | $-6.70+15.6% | $-7.94-2.3% | $-7.76 | N/A |
BIOA Balance Sheet
| Metric | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $305.1M-5.3% | $322.1M-6.3% | $343.8M-4.0% | $358.2M+6.2% | $337.4M | N/A | N/A | $25.9M |
| Current Assets | $290.8M-3.6% | $301.7M-7.1% | $324.8M-9.0% | $357.1M+6.1% | $336.5M | N/A | N/A | $25.3M |
| Cash & Equivalents | $215.6M-2.2% | $220.3M-14.4% | $257.5M-27.3% | $354.3M+5.9% | $334.5M | N/A | $174.0M+703.9% | $21.6M |
| Inventory | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Accounts Receivable | $515K-14.6% | $603K+67.0% | $361K | $0 | N/A | N/A | N/A | N/A |
| Goodwill | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $27.6M+0.9% | $27.4M-10.8% | $30.7M-12.6% | $35.1M+48.6% | $23.6M | N/A | N/A | $199.3M |
| Current Liabilities | $24.5M+7.3% | $22.8M-3.8% | $23.7M-14.5% | $27.8M+45.6% | $19.1M | N/A | N/A | $58.2M |
| Long-Term Debt | $0 | $0-100.0% | $1.1M-57.8% | $2.5M-36.5% | $3.9M | N/A | N/A | $8.2M |
| Total Equity | $277.5M-5.9% | $294.8M-5.9% | $313.2M-3.1% | $323.1M+3.0% | $313.7M+259.2% | -$197.1M-6.3% | -$185.5M-7.0% | -$173.4M |
| Retained Earnings | -$307.5M-7.0% | -$287.3M-8.1% | -$265.7M-5.1% | -$252.8M-9.1% | -$231.7M | N/A | N/A | -$181.7M |
BIOA Cash Flow Statement
| Metric | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$16.0M+19.7% | -$20.0M-15.0% | -$17.4M-237.9% | -$5.1M+65.6% | -$14.9M+5.4% | -$15.8M-0.7% | -$15.7M-84.3% | -$8.5M |
| Capital Expenditures | $22K-86.2% | $159K-62.7% | $426K+1538.5% | $26K-91.5% | $305K+771.4% | $35K | $0 | $0 |
| Free Cash Flow | -$16.1M+20.2% | -$20.1M-13.1% | -$17.8M-244.5% | -$5.2M+66.1% | -$15.2M+3.7% | -$15.8M-0.9% | -$15.7M-84.3% | -$8.5M |
| Investing Cash Flow | $12.8M+182.1% | -$15.6M+79.9% | -$78.0M-299853.8% | -$26K+91.5% | -$305K-771.4% | -$35K | $0 | $0 |
| Financing Cash Flow | -$1.5M-2.9% | -$1.5M0.0% | -$1.5M-106.0% | $24.9M-86.9% | $190.7M+8088.4% | -$2.4M-101.4% | $168.0M+16750.2% | -$1.0M |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
BIOA Financial Ratios
| Metric | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Margin | -1126.6%-99.6pp | -1027.0%+106.4pp | -1133.4% | N/A | N/A | N/A | N/A | N/A |
| Net Margin | -982.0%-88.0pp | -894.0%-3.0pp | -891.0% | N/A | N/A | N/A | N/A | N/A |
| Return on Equity | -7.3%+0.0pp | -7.3%-3.2pp | -4.1% | N/A | -7.5% | N/A | N/A | N/A |
| Return on Assets | -6.6%+0.1pp | -6.7%-2.9pp | -3.8% | N/A | -6.9% | N/A | N/A | N/A |
| Current Ratio | 11.87-1.3 | 13.21-0.5 | 13.68+0.8 | 12.86-4.8 | 17.63 | N/A | N/A | 0.44 |
| Debt-to-Equity | 0.000.0 | 0.000.0 | 0.000.0 | 0.010.0 | 0.01 | N/A | N/A | -0.05 |
| FCF Margin | -782.2%+52.3pp | -834.5%+391.5pp | -1226.0% | N/A | N/A | N/A | N/A | N/A |
Similar Companies
Frequently Asked Questions
What is BioAge Labs Inc.'s annual revenue?
BioAge Labs Inc. (BIOA) reported $9.0M in total revenue for fiscal year 2025. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
Is BioAge Labs Inc. profitable?
No, BioAge Labs Inc. (BIOA) reported a net income of -$80.6M in fiscal year 2025, with a net profit margin of -896.1%.
What is BioAge Labs Inc.'s EBITDA?
BioAge Labs Inc. (BIOA) had EBITDA of -$92.6M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
How much debt does BioAge Labs Inc. have?
As of fiscal year 2025, BioAge Labs Inc. (BIOA) had $188.9M in cash and equivalents against $2.5M in long-term debt.
What is BioAge Labs Inc.'s operating margin?
BioAge Labs Inc. (BIOA) had an operating margin of -1031.5% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
What is BioAge Labs Inc.'s net profit margin?
BioAge Labs Inc. (BIOA) had a net profit margin of -896.1% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
What is BioAge Labs Inc.'s return on equity (ROE)?
BioAge Labs Inc. (BIOA) has a return on equity of -29.6% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is BioAge Labs Inc.'s free cash flow?
BioAge Labs Inc. (BIOA) generated -$82.3M in free cash flow during fiscal year 2025. This represents a -58.7% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is BioAge Labs Inc.'s operating cash flow?
BioAge Labs Inc. (BIOA) generated -$81.6M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are BioAge Labs Inc.'s total assets?
BioAge Labs Inc. (BIOA) had $294.9M in total assets as of fiscal year 2025, including both current and long-term assets.
What are BioAge Labs Inc.'s capital expenditures?
BioAge Labs Inc. (BIOA) invested $719K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does BioAge Labs Inc. spend on research and development?
BioAge Labs Inc. (BIOA) invested $74.0M in research and development during fiscal year 2025.
What is BioAge Labs Inc.'s current ratio?
BioAge Labs Inc. (BIOA) had a current ratio of 14.24 as of fiscal year 2025, which is generally considered healthy.
What is BioAge Labs Inc.'s debt-to-equity ratio?
BioAge Labs Inc. (BIOA) had a debt-to-equity ratio of 0.01 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is BioAge Labs Inc.'s return on assets (ROA)?
BioAge Labs Inc. (BIOA) had a return on assets of -27.3% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is BioAge Labs Inc.'s cash runway?
Based on fiscal year 2025 data, BioAge Labs Inc. (BIOA) had $188.9M in cash against an annual operating cash burn of $81.6M. This gives an estimated cash runway of approximately 28 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is BioAge Labs Inc.'s Piotroski F-Score?
BioAge Labs Inc. (BIOA) has a Piotroski F-Score of 1 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are BioAge Labs Inc.'s earnings high quality?
BioAge Labs Inc. (BIOA) has an earnings quality ratio of 1.01x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can BioAge Labs Inc. cover its interest payments?
BioAge Labs Inc. (BIOA) has an interest coverage ratio of -132.5x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is BioAge Labs Inc.?
BioAge Labs Inc. (BIOA) scores 40 out of 100 on our Financial Profile, indicating moderate overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.